Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing
Activist Yakira Capital Management publicly called on Atrium Therapeutics' Board to initiate a strategic review, curtail cash spending, and explain its October 8 decision to raise $50 million via private placement at roughly $7.93 per share. Yakira estimates Atrium held about $254 million in net cash at Q3-end (~$14.85 per share), meaning the stock trades below cash value, and highlights up to $1.35 billion in R&D milestones plus $825 million in commercial milestones from the Bristol Myers Squibb collaboration, with $30 million already earned.
Key figures
- Deal Value Usd
- 50000000
- Offering Price
- 7.93
- Poc timing
- second half of 2027
- Stock decline
- approximately 44% from pre-HARBOR level
- Bms rd milestones
- $1.35 billion
- Estimated net cash
- $254 million (Q3-end, per Yakira estimate, ~$14.85/share)
- Net cash per share
- 14.85
- Collab spending cap
- $40 million cumulative
- Pre harbor share price
- roughly $14
- Private placement shares
- 5.17 million common shares
- Bms commercial milestones
- $825 million
- Milestones earned to date
- $30 million
- Pre funded warrant shares
- 1.13 million shares
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.